Psychedelics in psychiatry: from promise to translation
Yi Zhang, Yongbo Zheng, Meng Jin, Lin Lu
The British Journal of Psychiatry August 10, 2026 DOI: 10.1192/bjp.2026.10749 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Key points | Argues that psychedelics hold promise for psychiatry but that clinical translation remains premature, requiring coordinated advances in mechanistic study, clinical implementation, regulatory governance, and public discourse. |
Abstract
Psychedelics hold promise for psychiatry, yet clinical translation remains premature. Addressing the challenges of psychedelics in psychiatry requires advances in mechanistic study, clinical implementation, regulatory governance and public discourse in parallel.
Citations in the library
Cites 5
- The neural basis of psychedelic action. Nature Neuroscience October 24, 2022
- Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nature Communications December 15, 2023
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research May 1, 2024
- Is it now time to prepare psychiatry for a psychedelic future? The British Journal of Psychiatry May 20, 2024
- Rethinking placebo-controlled clinical trials in psychedelic therapies for psychiatric illness. The British Journal of Psychiatry July 21, 2025